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Characterization of assembly of recombinant type IV collagen
a3, a4, and a5 chains in transfected cell strains.
Background. Alport syndrome is caused by mutations in type
IV collagen a3, a4, and a5 genes. Immunohistochemical analy-
ses of kidney sections from normal individuals and Alport syn-
drome patients have suggested that the a3(IV), a4(IV), and
a5(IV) chains form a heterotrimer in the glomerular basement
membrane (GBM) and that a defect in any one of the chains
disrupts the assembly of the three chains, resulting in Alport
syndrome.
Methods. We established stable transformants of HEK293
cells that expressed mouse a3(IV) and/or a4(IV) and/or a5(IV)
chains. Using cell extracts and culture media of these cells, ex-
periments were performed to determine whether or not the
a3(IV) and a4(IV) chains were coimmunoprecipitated with the
a5(IV) chain. Moreover, we examined complex formation of
mutant a5(IV) chain containing either a deletion or substitu-
tion mutation with the a3(IV) and a4(IV) chains.
Results. The established cell strains were named according to
their transfected a(IV) chains. The a3(IV) and a4(IV) chains
were coimmunoprecipitated with the a5(IV) chain in a345 cells
but not in a35 and a45 cells. These chains were not coimmuno-
precipitated with the a5(IV) chain, which lacked either a col-
lagenous domain or NC1 domain. The ability of the a5(IV)
chain with either a G1182R or C1573R substitution, corre-
sponding to previously reported mutations in Alport syndrome
patients, to form a complex with a3(IV) and a4(IV) chains was
diminished.
Conclusion. The findings indicate that a3(IV), a4(IV), and
a5(IV) chains form a complex, which is a heterotrimer, and that
a defect in complex formation might be one of the molecular
mechanisms underlying the pathogenesis of Alport syndrome.
Alport syndrome is a hereditary disorder characterized
by a progressive form of glomerulonephritis that is fre-
quently associated with sensorineural deafness and ocu-
lar abnormalities. Electron microscopic analysis of renal
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biopsies from Alport syndrome patients shows typical ul-
trastructural changes such as regional thinning, thicken-
ing, and splitting in the glomerular basement membrane
(GBM). Alport syndrome is genetically heterogeneous
with X-linked, autosomal-recessive, and much less com-
mon autosomal-dominant forms of inheritance [1]. Most
cases of Alport syndrome are caused by mutations in the
type IV collagen a5 gene (COL4A5) on the X chromo-
some [2]. The rarer autosomal forms, which account for
approximately 15% of Alport syndrome cases, are caused
by mutations in the type IV collagen a3 and a4 genes
(COL4A3 and COL4A4) [3]. These latter two collagen
genes are localized in a head-to-head fashion separated
by a common promoter on the long arm of chromosome
2 [4].
Type IV collagen is a family of six distinct a chains,
a1(IV), a2(IV), a3(IV), a4(IV), a5(IV), and a6(IV).
Each chain consists of a short 7S domain at the amino
terminus, a long collagenous domain of approximately
1400 residues, with Gly-X-Y repeats that are frequently
interrupted by short noncollagenous sequences, and a
noncollagenous (NC1) domain of about 230 residues at
the carboxyl terminus [1]. Two a1(IV) chains and one
a2(IV) chain form a heterotrimer, [a1(IV)2]a2(IV), and
are ubiquitously present in most basement membranes
[5]. In contrast, the other a chains are minor components
in the basement membranes with restricted tissue dis-
tributions. The a5(IV) and a6(IV) chains are abundant
in the basement membranes of smooth muscle cells in
the esophagus, uterus, bladder, and some blood vessels
as well as in the basement membrane of the epidermis.
The a3(IV) and a4(IV) chains show more restricted tis-
sue distributions. These two chains are present only in the
kidney, lung, and brain [6]. In the kidney, the a3(IV) and
a4(IV) chains are present mainly in the GBM. The a5(IV)
chain is also present in the GBM, but the a6(IV) chain is
absent. Moreover, the a5(IV) chain colocalizes with the
a6(IV) chain in the basement membranes of Bowman’s
capsules that lack the a3(IV) and a4(IV) chains [7]. These
distribution patterns suggest that there are two kinds of
type IV collagen molecule other than [a1(IV)]2a2(IV):
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one containing a3(IV), a4(IV), and a5(IV) chains, and
the other containing a5(IV) and a6(IV) chains.
In X-linked Alport syndrome, most mutations in the
COL4A5 gene lead to the disappearance of not only
the a5 chain but also a3(IV), a4(IV), and a6(IV) chains
from the basement membranes in the kidney [8]. On the
other hand, in autosomal Alport syndrome, mutation in
either the COL4A3 or COL4A4 gene leads to the disap-
pearance of a3(IV), a4(IV), and a5(IV) chains from the
GBM, but the a5(IV) chain is retained in the basement
membrane of Bowman’s capsules [9]. These findings sup-
port the above speculation.
In this study, to confirm the assembly of a3(IV),
a4(IV), and a5(IV) chains, we established seven cell
lines that stably express recombinant mouse a3(IV)
and/or a4(IV) and/or a5(IV) chains, and we analyzed the
assembly of these chains in cell extracts and culture me-
dia of the cells using an immunoprecipitation method.
We also introduced two individual substitution muta-
tions, G1182R (Gly1182 to Arg) and C1573R (Cys1573 to
Arg), into the a5(IV) expression vector. These two muta-
tions correspond to those previously reported in X-linked
Alport syndrome patients [8, 10]. In order to understand
the molecular mechanisms underlying the pathogenesis
of Alport syndrome, we established cell lines that coex-
press the mutant a5(IV) chain with the wild-type a3(IV)
and a4(IV) chains, and we analyzed the assembly of these
a(IV) chains.
METHODS
Construction of plasmids
The mouse cDNA encoding NC1 domains of the
a3(IV), a4(IV), and a5(IV) chains were amplified by
polymerase chain reaction (PCR) from a kZAP II mouse
kidney cDNA library using three pairs of primers based
on published sequence data [11]. Mouse cDNA clones
for the a3(IV), a4(IV), and a5(IV) chains were isolated
from the library using the amplified cDNAs as probes.
The 5′ regions of the clones were successively amplified
by PCR for probes, and screenings of the cDNA library
were repeated using the probes. Full-length mouse
cDNAs for each chain were constructed from a series
of some overlapping clones. PCR amplification of the
3′ region of each cDNA was performed in order to
alter the stop codon to the DNA sequence encoding an
epitope tag and/or an additional restriction endonucle-
ase site for subcloning. DNA sequence analyses were
performed to exclude the possibility of nucleotide miss-
incorporation in PCR. The myc epitope EQKLISEEDL,
a stop codon and an XbaI site were introduced into
the COL4A3 cDNA using a pair of PCR primers,
S3/R3 (5′-TCATCTTCACCCGACACAGT-3′/5′-GCTC
TAGATTACAGATCCTCTTCTGAGATGAGTTTTT
GTTCATGTCTTTTCTTCATGCACA-3′). The mod-
ified COL4A3 cDNA, including the entire open
reading frame, was cloned into the expression vector
pcDNA3.1/Hygro (Invitrogen, Carlsbad, CA, USA)
containing a hygromycin resistance gene. The COL4A4
cDNA, including the entire open reading frame, was
cloned into the expression vector pcDNA6/V5-HisA
(Invitrogen), which contains a carboxyl-terminal tag
encoding the V5 epitope GKPIPNPLLGLDST and a
blasticidin resistance gene, after modification of a stop
codon to the XbaI restriction site using a pair of PCR
primers, S4/R4 (5′-CTGGGGCACCTGGCGAGAAG-
3′/5′-TCTGAGCTGTGCTTCATGCAAAC-3′). The
FLAG epitope DYKDDDDK, a stop codon and
an XhoI restriction site were introduced into the
COL4A5 cDNA using a pair of PCR primers, S5/R5
(5′-CATTCATTAGTCGATGTGCA-3′/5′-CTCGAGC
TACTTGTCATCGTCGTCCTTGTAATCTGTCCTCT
TCATGCATACTT-3′). The resultant COL4A5 cDNA,
including the entire open reading frame, was cloned
into the expression vector pCAGGS containing a
cytomegalovirus enhancer, a chicken b-actin promoter,
and a neo cassette [12].
Cell culture and transfections
The human embryonic kidney cell line 293 (HEK293)
was cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% fetal calf serum (FCS).
HEK293 cells (5 × 104 cells) were transfected with
0.5 lg of the COL4A3, COL4A4, or COL4A5 cDNA
expression plasmid by using Lipofectamine PLUSTM
reagent (Gibco BRL, Gaithersburg, MD, USA). Trans-
fectants were selected in medium containing 200 lg/mL of
Hygromycin B (Gibco BRL) for COL4A3, 8 lg/mL of
blasticidin S (Funakoshi, Tokyo, Japan) for COL4A4,
and 400 lg/mL of G418 (Gibco BRL) for COL4A5.
Resistant clones were screened for protein expression
from cell extracts by Western blot analysis using anti-myc
(Invitrogen), anti-V5 (Invitrogen) and anti-FLAG
(Sigma Chemical Co., St. Louis, MO, USA) monoclonal
antibodies. These clones were named a3, a4, and a5 cells
according to their transfected cDNAs. a3 cells were trans-
fected with the COL4A4 or COL4A5 cDNA expression
plasmid, and established permanent transfectants were
named a34 and a35 cells, respectively. a4 cells and a34
cells were transfected with the COL4A5 cDNA expres-
sion plasmid, and stably transfected clones were named
a45 and a345 cells, respectively.
Immunopurification of a 5(IV) protein
and associated proteins
The clonal cell lines were grown to confluence on
100 mm Petri dishes and extracted in 1 mL of NETN
[50 mmol/L Tris-HCl, pH 7.8, 150 mmol/L NaCl,
1 mmol/L ethyelenediaminetetraacetic acid (EDTA),
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1% Nonidet P-40, 1 mmol/L dithiothreitol (DTT),
0.5 mmol/L phenylmethylsulfonyl fluoride (PMSF),
1 lg/mL pepstatin A, and 1 lg/mL leupeptin]. Conflu-
ent cells were also incubated for an additional 24 hours
in 3 mL of serum-free medium. The medium was col-
lected and equilibrated to 1 mmol/L EDTA, 0.5 mmol/L
PMSF, 1 lg/mL pepstatin A, and 1 lg/mL leupeptin.
One milliliter of the cell extract or culture medium was
then incubated with 30 lL of anti-FLAG M2 affinity
gel (Sigma Chemical Co.) overnight at 4◦C. The gel was
washed five times with 10 V of ice-cold NETN. The bound
proteins were eluted from the affinity gel by compet-
ing FLAG-peptide (Sigma Chemical Co.) at a concentra-
tion of 200 lg/mL in Tris-buffered saline and subjected
to 6% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) under nonreducing conditions.
The bound proteins were also extracted by boiling in
SDS sample buffer containing 6% 2b-mercaptoethanol
and then separated by 7.5% SDS-PAGE. Proteins were
then analyzed by immunoblotting with anti-myc, anti-V5,
and anti-FLAG monoclonal antibodies and then with
an alkaline phosphatase-conjugated horse antimouse
IgG antibody. Color development was performed using
nitro blue tetrazolium (NBT) and 5-bromo-4-chloro-3-
indolylphosphate (BCIP).
Co-culture of a3, a4, and a5 cells
a3 cells (1 × 106), a4 cells (1 × 106), and a5 cells (1 ×
106) were co-cultured on a 100 mm Petri dish for 48 hours
until confluence. At the end of the culture, cells were
extracted in NETN. Confluent cells were also incubated
for an additional 24 hours in serum-free medium, and the
medium was collected.
In vitro mutagenesis
In vitro mutagenesis reactions were carried out
on COL4A5 cDNA in the pCAGGS vector by PCR
based on a method described by Imai et al [13] with
modifications. Briefly, oligonucleotide primers were
designed in inverted tail-to-tail directions to amplify the
cloning vector together with the insert. A point mutation
for an amino acid substitution was introduced into the
middle of one primer. A deletion was generated by
amplification with primers that have a corresponding
gap between their 5′ ends. The primers used were 5′-TC
TGTTGCCCATGGATTCCT - 3′/5′ -ACTGCAGTCAC
ATTTTGATC for COL (deletion of 42-1462 amino
acid residues), 5′-GATTACAAGGACGACGATGA-
3′/5′-GGTGGTTCCAGGGGGTCCTG-3′ for NC1
(deletion of 1463-1691 amino acid residues), 5′-AGGA
CAAAAGCGAGAACCAGG-3′/5′ - GCTGGCCCAG
GAATGCCATC-3′ for G1182R, and 5′-CTGCAACA
TTAACAACGTTT-3′/5′ - CAGCTGGCGCCTCACGC
ACTG-3′ for C1573R. After phosphorylation of the
5′ end of each primer, parental cDNA inserted in the
pCAGGS vector was amplified using KOD-Plus DNA
polymerase (Toyobo, Osaka, Japan) with these primers
for fifteen consecutive cycles. After digestion of the
parental DNA with DpnI, the amplified DNA was
self-ligated using a ligation-high kit (Toyobo) and trans-
fected into DH5a-competent cells. The plasmids were
prepared, and DNA sequencing confirmed objective
mutations and excluded the possibility of additional
mutations having been introduced elsewhere in the
mutant COL4A5 cDNA. Mutant-type COL4A5 cDNA
expression plasmids were constructed by replacement
of a part of the wild-type cDNA with the mutant-type
cDNA using appropriate restriction endonucleases.
RESULTS
Recombinant production of a3(IV), a4(IV), and a5(IV)
The cDNAs, including the entire open reading frames
for the mouse a3(IV), a4(IV), and a5(IV) chains,
were cloned into the eukaryotic expression vectors
pcDNA3.1/Hygro, pcDNA6/V5-His A, and pCAGGS,
respectively. These expression plasmids were transfected
into HEK293 cells, and stable transfectants were estab-
lished. Since each recombinant protein was expressed
as a fusion protein containing a short epitope tag, myc
for the a3(IV) chain, V5 for the a4(IV) chain, and
FLAG for the a5(IV) chain, on the carboxyl-terminal
region, the presence of the recombinant protein was con-
firmed using anti-epitope tag antibodies. Immunoblot
analyses with anti-myc, anti-V5, and anti-FLAG mon-
oclonal antibodies revealed the expressions of the re-
combinant a3(IV), a4(IV), and a5(IV) chains both in
the cell extracts and in serum-free culture media that
had been concentrated tenfold by Microcon YM-100
(Millipore, Bedford, MA, USA) (data not shown). These
results indicate that the transfected HEK293 cells pro-
duced the recombinant a3(IV), a4(IV), or a5(IV) chain,
which was secreted into the culture medium. The sta-
bly transfected HEK293 cells were named a3, a4, and a5
cells, respectively. Then, a3 cells were transfected with the
expression plasmid for recombinant a4(IV), and an a34
cell line that expressed both a3(IV) and a4(IV) chains
was established. In the same manner, a35 cells that ex-
pressed both a3(IV) and a5(IV) chains, a45 cells that
expressed both a4(IV) and a5(IV) chains, and a345 cells
that expressed a3(IV), a4(IV), and a5(IV) chains were
established and used for further experiments. Figure 1
shows the expressions of recombinant a3(IV), a4(IV),
and a5(IV) chains in the cell extracts or culture media of
a34, a35, a45, and a345 cells under reducing conditions.
Expected recombinant proteins were found both in each
cell extract and in each culture medium. In the a345 cells,
the a3(IV), a4(IV), and a5(IV) chains were expressed to-
gether. The size of every recombinant protein with almost
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Fig. 1. Synthesis and secretion of recombinant a3(IV), a4(IV), and
a5(IV) chains in transfected human embryonic kidney 293 (HEK293)
cells. Cell extracts (A) and tenfold concentrated culture media (B) of
HEK293 cells transfected with mouse a3(IV), a4(IV), and a5(IV) cD-
NAs were subjected to 7.5% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) under reducing conditions followed
by immunoblot analyses using monoclonal antibodies against epitope
tags, myc for a3(IV), V5 for a4(IV), and FLAG for a5(IV). The nu-
merals in a345, a34, a35, and a45 mean the kind of a(IV) cDNAs
transfected into HEK293 cells. The numeral 293 means untransfected
HEK 293 cells as a control.
185 kD was compatible to the protein size deduced from
amino acid sequences. The expression of a4(IV) chain
was weak compared to those of a3(IV) and a4(IV) chains
but was sufficient to analyze the assembly of a3(IV),
a4(IV), and a5(IV) chains. Moreover, the amount of
a4(IV) chain in the culture medium of either a345 or a45
cells was less than that in the culture medium of a34 cells.
Other clones of these cells also showed similar expres-
sion patterns (data not shown). The reason for this is not
clear. The coexpressed a5(IV) chain might have had an
effect on the secretion of the a4(IV) chain. Immunoblot
analyses of the whole-cell extracts and concentrated
culture media under nonreducing conditions showed high
background, and bands with high molecular weight were
indistinct (data not shown).
Coimmunoprecipitation of a3(IV)
and a4(IV) with a5(IV)
In order to analyze complex formation of a3(IV),
a4(IV), and a5(IV) chains, we examined the interaction
among these proteins by coimmunoprecipitation analy-
ses using an anti-FLAG antibody. Whole-cell extracts or
culture media of HEK293 cells transfected with a(IV)
chains were immunoprecipitated with the anti-FLAG
antibody. The immunoprecipitants were analyzed by
SDS-PAGE and subsequent immunoblotting with anti-
myc, anti-V5, and anti-FLAG antibodies. As shown in
Figure 2, two bands of a5(IV) chain with a molecular
mass of either approximately 185 kD or 580 kD appeared
in a345 cells, whereas only a single band with a molec-
ular mass of almost 185 kD was seen in a5 cells under
nonreducing conditions. The a3(IV) and a4(IV) chains
were coimmunoprecipitated with the a5(IV) chain and
detected as bands migrating around 580 kD, the expected
size of a heterotrimer, in a345 cells. These findings indi-
cate that the a3(IV), a4(IV), and a5(IV) chains form a
heterotrimer and that the a5(IV) chain does not form a
homotrimer. In a345 cells, the intensity of the 580 kD
band of a heterotrimer was much fainter than that of the
185 kD band of an a5(IV) chain monomer in immunoblot
analyses. When the polyacrylamide gel was stained with
Coomassie brilliant blue, the monomer band was ob-
served clearly, but the heterotrimer band was hardly
detectable (data not shown). These findings indicate that
the majority of a5(IV) chains exist as monomers in both
the cell extract and culture medium of a345 cells. Un-
der reducing conditions, either coimmunoprecipitated
a3(IV) or a4(IV) chain with the a5(IV) chain appeared
as a single band with a molecular mass of 185 kD (Fig. 3).
Since the bands under reducing conditions were clearer
than those with a molecular mass of 580 kD under nonre-
ducing conditions, immunoprecipitation analyses of var-
ious cell strains were done under reducing conditions.
As shown in Figure 3, neither the a3(IV) chain nor the
a4(IV) chain was coimmunoprecipitated with the a5(IV)
chain by the anti-FLAG antibody in the cell extracts and
culture media of a35 and a45 cells, in contrast to the find-
ings for cell extract and culture medium of a345 cells.
These results indicate that the a5(IV) chain does not
form a complex with either the a3(IV) or a4(IV) chain
alone.
To determine whether the a3(IV), a4(IV), and a5(IV)
monomers in the mixture of whole-cell extracts or culture
media of a3, a4, and a5 cells form a ternary complex, the
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Fig. 2. Formation of a heterotrimer of
a3(IV), a4(IV), and a5(IV) chains in a 345
cells. Cell extracts (A) and culture me-
dia (B) of a345 (lanes 1, 4, and 7), a5
(lanes 2, 5, and 8) and control human em-
bryonic kidney 293 (HEK293) (lanes 3, 6,
and 9) cells were incubated with anti-FLAG
M2 affinity gel. After washing the gel, the
bound proteins eluted by competing FLAG-
peptide were analyzed by 6% sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) under nonreducing conditions
followed by immunoblot analyses with anti-
FLAG, anti-myc, and anti-V5 monoclonal an-
tibodies. The positions of the monomer (M)
and heterotrimer (T) are indicated.
whole-cell extract and culture medium of co-cultured a3,
a4, and a5 cells were immunoprecipitated with the anti-
FLAG antibody. As shown in Figure 4, the a3(IV) and
a4(IV) chains were not coimmunoprecipitated with the
a5(IV) chain by the anti-FLAG antibody either in the
cell extract or culture medium of co-cultured a3, a4, and
a5 cells. These results suggest that a complex of a3(IV),
a4(IV), and a5(IV) chains may be formed in a345 cells
followed by secretion into the culture medium.
Effect of deletion in a5(IV) on ternary complex
formation of a3(IV), a4(IV), and a5(IV)
Each chain of a3(IV), a4(IV), and a5(IV) consists
of a long collagenous domain of approximately 1400
residues with Gly-X-Y repeats and an NC1 domain of
about 230 residues at the carboxyl terminus. To deter-
mine whether a5(IV), in which each domain is deleted,
forms a ternary complex with a3(IV) and a4(IV) chains
in this assay system, we established cell lines a345NC1
and a345COL. a345NC1 cells express mutant a5(IV)
protein lacking the NC1 domain with a3(IV) and a4(IV)
chains, and a345COL cells express mutant a5(IV) lack-
ing the collagenous domain with a3(IV) and a4(IV)
chains. As shown by the results of immunoblot analy-
sis presented in Figure 5A, the truncated a5(IV) pro-
tein with a size of 160 kD was detected with the a3(IV)
and a4(IV) chains in a345NC1 cell extract. Neither
the a3(IV) chain nor the a4(IV) chain was coimmuno-
precipitated with the truncated a5(IV) protein using the
anti-FLAG antibody in a345NC1 cell extracts (Fig. 5B).
Figure 5C shows the expression of the mutant a5(IV)
protein that has a deletion of the collagenous domain
with a3(IV) and a4(IV) chains in a345COL cells. The
size of the truncated protein was about 28 kD, consis-
tent with the size expected from amino acid sequence.
This mutant a5(IV) protein also did not coimmunopre-
cipitate the a3(IV) and a4(IV) chains using the anti-
FLAG antibody in a345COL cell extracts (Fig. 5D).
These results indicate that both the collagenous domain
and the NC1 domain in the a5(IV) chain are indis-
pensable for the formation of a complex with a3(IV)
and a4(IV) chains in this immunoprecipitation assay
system.
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Fig. 3. Coimmunoprecipitation of a3(IV)
and a4(IV) with a5(IV) in human embry-
onic kidney 293 (HEK293) cells transfected
with a (IV) cDNAs. Cell extracts (A) and cul-
ture media (B) of HEK293 cells transfected
with a(IV) cDNAs were incubated with anti-
FLAG M2 affinity gel. After washing the gel,
the bound proteins were analyzed by 7.5%
sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) under reduc-
ing conditions and immunoblotting with anti-
FLAG, anti-myc, and anti-V5 monoclonal an-
tibodies.
Effect of amino acid substitution of a5(IV) on ternary
complex formation of a3(IV), a4(IV), and a5(IV)
Site-directed mutagenesis was used to generate a
glycine-to-arginine substitution at the amino acid residue
1182 (G1182R) and a cysteine-to-arginine substitution
at the amino acid residue 1573 (C1573R) in the mouse
a5(IV) chain. We established cell lines a345G1182R and
a345C1573R. a345G1182R cells express a mutant a5(IV)
chain containing the G1182R substitution with a3(IV)
and a4(IV) chains, and a345C1573R cells express a mu-
tant a5(IV) chain that contains the C1573R substitution
with a3(IV) and a4(IV) chains.
In the extract of a345G1182R cells, the a3(IV) and
a4(IV) chains were coimmunoprecipitated with the
G1182R-type a5(IV) chain using the anti-FLAG anti-
body. The amounts of a3(IV) and a4(IV) chains pre-
cipitated with the mutant a5(IV) chain were almost the
same as the amounts of those chains precipitated with
the wild-type a5(IV) chain (Fig. 6A). In culture medium,
the a3(IV) and a4(IV) chains were coimmunopre-
cipitated with the G1182R-type a5(IV) chain, but
the amounts of the coimmunoprecipitated a3(IV) and
a4(IV) chains in a345G1182R cells were markedly de-
creased compared to the amounts of those chains in a345
cells (Fig. 6B). These results suggest that the G1182R-
type a5(IV) chain is able to form a complex with a3(IV)
and a4(IV) chains and that the amount of secretion
and/or degree of stability of the formed complex in
a345G1182R cells might be decreased. In the extract of
a345C1573R cells, the C1573R-type a5(IV) chain was
immunoprecipitated by the anti-FLAG antibody, but the
coimmunoprecipitaiton of either the a3(IV) chain or
the a4(IV) chain was hardly seen (Fig. 6A). Moreover,
the C1573R-type a5(IV) chain, as well as the a3(IV) and
a4(IV) chains, was not immunoprecipitated by the anti-
FLAG antibody in culture medium of a345C1573R cells
(Fig. 6B). These findings indicate that the C1573R sub-
stitution in the a5(IV) chain impairs the ability of the
a5(IV) chain to form a complex with a3(IV) and a4(IV)
chains and to be secreted from cells even in monomeric
form.
DISCUSSION
Collagen is the most abundant protein in the mam-
malian body. Nineteen different types of collagen,
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Fig. 4. Immunoprecipitation in co-cultured
a3, a4, and a5 cells. Cell extracts (A) and cul-
ture media (B) of a345 cells and co-cultured
a3, a4, and a5 cells (a3a4a5) were immuno-
precipitated with an anti-FLAG monoclonal
antibody and analyzed by 7.5% sodium dode-
cyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE) under reducing conditions
followed by immunoblot analyses with anti-
FLAG, anti-myc, and anti-V5 monoclonal
antibodies.
consisting of more than 30 kinds of collagen chains, have
so far been identified. Three collagen chains are assem-
bled and form a collagen molecule with a triple heli-
cal structure. Whether the molecule is a homotrimer or
heterotrimer depends on the type of collagen. Collagen
molecules differ in structure, expression, tissue distri-
bution, and function. Mutations have been reported in
more than half of the known collagen genes and have
been shown to result in human genetic disorders such as
osteogenesis imperfecta, Ehlers-Danlos syndrome, and
dystrophic epidermolysis bullosa [14]. Type IV colla-
gens, which contain six distinct a chains, a1(IV), a2(IV),
a3(IV), a4(IV), a5(IV), and a6(IV), are found in base-
ment membranes with a tissue-specific distribution pat-
tern. Two a1(IV) chains and one a2(IV) chain form
a heterotrimer, [a1(IV)]2a2(IV) and exist in almost all
basement membranes [15, 16]. In immunohistochemical
analyses of kidney sections, a3(IV), a4(IV), and a5(IV)
chains show a similar staining pattern in the GBM. In Al-
port syndrome patients, mutations in either the a3(IV),
a4(IV), or a5(IV) chain usually lead to an absence of
all three chains in the GBM. These facts suggest that
the three chains form a heterotrimer in the GBM and
that most mutations of the chains in Alport syndrome
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Fig. 5. Effect of deletion in a5(IV) on ternary complex formation
of a3(IV), a4(IV), and a5(IV). a34 cells were transfected with
a5(IV) that lacks either the NC1 domain or collagenous domain, and
stable transformants were established (a345NC1 and a345COL
cells). Immunoblot analyses of extracts from a345NC1 (A) and
a345COL cells (C) were performed. Extracts from a345NC1 (B)
and a345COL cells (D) were immunoprecipitated with an anti-FLAG
monoclonal antibody and then subjected to 7.5% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reduc-
ing conditions followed by immunoblot analyses with anti-FLAG, anti-
myc, and anti-V5 monoclonal antibodies. Arrowheads in D indicate
immunoprecipitated a5(IV) chains. Two strongly reacted bands seen
in all lanes in (D) are heavy and light chains of anti-FLAG antibody
eluted from affinity gel.
cause a defect in assembly of the three chains [6–9]. Re-
cently, Gunwar et al [17] analyzed truncated triple-helical
molecules purified from the GBM and identified a novel
disulfide cross-linked network of a3(IV), a4(IV), and
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Fig. 6. Effect of amino acid substitution of a5(IV) on ternary com-
plex formation of a3(IV), a4(IV), and a5(IV). a34 cells were trans-
fected with either G1182R or C1573R mutant-type a5(IV), and stable
transformants were established (a345G1182R and a345C1573R cells).
Cell extracts (A) and culture media (B) of a345, a345G1182R, and
a345C1573R cells were immunoprecipitated with an anti-FLAG mon-
oclonal antibody and then subjected to 7.5% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing con-
ditions followed by immunoblot analyses with anti-FLAG, anti-myc,
and anti-V5 monoclonal antibodies.
a5(IV) chains. They also showed that the NC1 domain
may contain a recognition sequence for the assembly of
a3(IV), a4(IV), and a5(IV) chains by using native and
recombinant NC1 domains of a1(IV) to a6(IV) chains
[18]. On the other hand, Heikkila et al [19] showed that a
recombinant human a5(IV) chain, which was expressed
by using an adenovirus vector in human HT1080 cells
that normally express a1(IV) to a5(IV) chains, assembled
in a heterotrimer with endogenous a3(IV) and a4(IV)
chains.
In this study, we established HEK293 transfectants
expressing recombinant mouse a3(IV) and/or a4(IV)
and/or a5(IV) chains. HEK293 cells are known to
synthesize few, if any, extracellular matrix proteins and
to produce recombinant proteins in large quantity using
genetic engineering techniques [20–22]. In the present
study, we used mouse, not human, COL4A3, COL4A4,
and COL4A5 cDNAs. Tissue distributions of type IV
collagen a chains in mice are the same as those in hu-
mans [11, 23]. Electron microscopic analysis of the GBM
from COL4A3 knockout mice showed typical changes
found in patients with Alport syndrome, and no staining
for a3(IV), a4(IV), and a5(IV) chains was detected in
the GBM. It has also been shown that COL4A3 knock-
out mice develop proteinuria at 1 to 2 months of age and
die of renal failure by 3 to 4 months of age [24, 25]. These
findings indicate that there might be no differences in the
essential roles of a3(IV), a4(IV), and a5(IV) chains in
the GBM in mice and humans.
Each chain of a3(IV), a4(IV), and a5(IV) was present
both in the cell extracts and culture media of a3, a4, and
a5 cells. The ability of a3(IV), a4(IV), and a5(IV) chains
to be secreted is in agreement with findings previously re-
ported by Leinonen et al [26]. They established HEK293
cells that stably express the a3(IV) chain and showed
that the recombinant a3(IV) chain was secreted as a sin-
gle polypeptide chain. It has also been reported that the
monomer a1(IV) chain was secreted as a random coil
structure in CHO cells overexpressing the a1(IV) chain
[27]. In the present examination of immunoprecipitation
using cell extracts and culture media by an anti-FLAG
monoclonal antibody, the a3(IV) and a4(IV) chains were
coimmunoprecipitated with the a5(IV) chain in a345
cells, but neither the a3(IV) chain nor the a4(IV) chain
was coimmunoprecipitated with the a5(IV) chain in a35
and a45 cells. These findings suggest that coexpression of
the a3(IV), a4(IV), and a5(IV) chains is necessary for
formation of a complex, which is a heterotrimer. A com-
plex was not formed in cell extract or culture medium of
co-cultured a3, a4, and a5 cells, indicating that a3(IV),
a4(IV), and a5(IV) chains might be assembled into a het-
erotrimer in a345 cells and then secreted into the culture
medium. This speculation is compatible with the fact that
collagen chains associate and are folded with some chap-
erone proteins such as heat shock protein 47 (HSP47) in
the cytoplasm and then the correctly formed heterotrimer
is secreted [14]. HSP47 specifically interacts with various
types of collagen and acts as a collagen-specific molecular
chaperone that facilitates normal collagen biosynthesis
[28].
Since the association among collagen chains occurs in a
carboxyl-terminal to amino-terminal direction, the NC1
domain, which is located in the carboxyl-terminal end, is
thought to play a crucial role in complex formation. In
fact, in in vitro assembly studies using purified native and
recombinant a1(IV) to a5(IV) NC1 monomers of about
230 amino acids, two kinds of complex were formed.
One contained a1(IV) and a2(IV) NC1 monomers, and
the other contained a3(IV), a4(IV), and a5(IV) NC1
monomers [18]. In our experiment, a5(IV) lacking an
NC1 domain did not form a complex with a3(IV) and
a4(IV) chains. This finding supports the speculation that
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the NC1 domain is important for the assembly of a3(IV),
a4(IV), and a5(IV) chains. On the other hand, a5(IV)
lacking a collagenous domain was not coimmunoprecip-
itated with a3(IV) and a4(IV) chains, indicating that if
NC1domains of a3(IV), a4(IV), and a5(IV) chains are
associated, the stability of the assembly is not sufficient
for coimmunoprecipitation in our present experimental
conditions.
In type IV collagen, single triple-helical molecules as-
sociated at the carboxyl termini (NC1-to-NC1) forming
dimmers and at the amino termini forming tetramers
[5]. In the 7S domain at the amino terminus, there are
numerous hydroxylysine-linked disaccharide units and
an asparagine-linked oligosaccharide unit. These carbo-
hydrate units play an important role in the formation
and stabilization of the tetramer [29, 30]. It is not clear
whether the recombinant a(IV) chains in this study were
glycosylated or not.
Alport syndrome is caused by mutations in the
COL4A3, COL4A4, and COL4A5 genes [2, 3]. The muta-
tions can cause structural and pathophysiologic changes
in collagen chains, resulting in GBM abnormalities. The
changes may affect the assembly and folding of three
a(IV) chains into a triple-helical molecule as well as the
stability of the helix structure. Almost all of the point
mutations previously reported in Alport syndrome were
generated by substitution of either glycine residues in the
collagenous domain or conserved amino acids in the NC1
domain [1]. We introduced a G1182R or C1573R substi-
tution into the mouse a5(IV) chain. The glycine at amino
acid 1182 in the mouse a5(IV) chain, corresponding to
glycine at amino acid 1182 in the human a5(IV) chain,
exists in the collagenous domain and corresponds to Gly
of a Gly-X-Y repeat. The cysteine at amino acid 1573 in
the mouse a5(IV) chain is in the middle of the NC1 do-
main and corresponds to cysteine at amino acid 1567 in
the human a5(IV) chain [23, 31]. Both the G1182R substi-
tution and the cysteine-to-arginine substitution at amino
acid 1567 (C1567R) in the human a5(IV) chain have been
identified in X-linked Alport syndrome patients. A male
patient with the G1182R substitution exhibited early oc-
currence of hematuria and ocular abnormalities but no
deafness and only mild renal impairment at the age of
16 years [8]. On the other hand, a male patient with the
C1567R substitution had a severe phenotype. He showed
early occurrence of hematuria, hearing loss, and ocular le-
sions, and end-stage renal failure occurred at the age of
16 years [10]. In the present study, the G1182R-type
a5(IV) chain had the ability to form a complex with
a3(IV) and a4(IV) chains to almost the same degree
as that of the wild-type a5(IV) chain in the cell ex-
tracts. However, the amount of complexes containing the
mutant a5(IV) chain was much less than that of com-
plexes containing the wild-type a5(IV) chain in the cul-
ture medium. Considering glycine is the only amino acid
small enough to fit into the center of the triple helix, the
G1182R-type a5(IV) chain might lead to reduced sta-
bility of the complex compared to the wild-type a5(IV)
chain. The C1573R-type a5(IV) chain hardly associated
with a3(IV) and a4(IV) chains. Moreover, the mutant
chain was not secreted from cells even in monomeric
form. It is likely that the C1573R mutation alters the pro-
tein conformation and that the ability to form a complex
and to be secreted is impaired. These findings suggest
that a defect in trimer formation by a3(IV), a4(IV), and
a5(IV) chains is one of the molecular mechanisms under-
lying the pathogenesis of Alport syndrome. On the other
hand, it is interesting that the patient with a C1567R-
type a5(IV) chain, which might possess no ability to
form trimers with a3(IV) and a4(IV) chains, exhibited a
more severe phenotype of Alport syndrome than did the
patient with a G1182R-type a5(IV) chain, which might
possess residual ability to form trimers with a3(IV) and
a4(IV) chains. Results of further studies using various re-
combinant mutants of a3(IV), a4(IV), and a5(IV) chains
might provide information on the correlations between
molecular defects and clinical phenotypes of Alport
syndrome.
ACKNOWLEDGMENTS
We thank Dr. Ichiro Satokata for kindly providing a mouse kid-
ney cDNA library, Dr. Masanari Nakayama for kindly providing PCR
primers, and Dr. Jun-ichi Miyazaki for kindly providing pCAGGS
expression vector. We also thank Dr. Toshio Kakihara for his helpful
advice.
Reprint requests to Takehiro Kobayashi, M.D., Division of Pedi-
atrics, Department of Homeostatic Regulation and Development, Niigata
University Graduate School of Medical and Dental Sciences, 1-757
Asahimachi-dori, Niigata City, 951-8510, Japan.
E-mail: takekoba@med.niigata-u.ac.jp
REFERENCES
1. TRYGGVASON K, MARTIN P: Alport syndrome and basement mem-
brane collagen, in The Metabolic and Molecular Bases of Inherited
Disease (vol. 4), edited by SCRIVER CR, BEAUDET AL, SLY WS, VALLE
D, New York, McGraw-Hill, 2001, pp 5453–5466
2. BARKER DF, HOSTIKKA SL, ZHOU J, et al: Identification of muta-
tions in the COL4A5 collagen gene in Alport syndrome. Science
248:1224–1226, 1990
3. MOCHIZUKI T, LEMMINK HH, MARIYAMA M, et al: Identification of
mutations in the a3(IV) and a4(IV) collagen genes in autosomal
recessive Alport syndrome. Nat Genet 8:77–82, 1994
4. MARIYAMA M, ZHENG K, YANG-FENG TL, REEDERS ST: Colocaliza-
tion of the genes for the a3(IV) and a4(IV) chains of type IV col-
lagen to chromosome 2 bands q35-q37. Genomics 13:809–813, 1992
5. HUDSON BG, REEDERS ST, TRYGGVASON K: Type IV collagen: struc-
ture, gene organization, and role in human disease. Molecular basis
of Goodpasture and Alport syndromes and diffuse leiomyomatosis.
J Biol Chem 268:26033–26036, 1993
6. ZHOU J, REEDERS ST: The a chains of type IV collagen, in Molecular
Pathology and Genetics of Alport Syndrome, edited by TRYGGVASON
K, Basel, Karger, 1996, pp 80–104
7. NINOMIYA Y, KAGAWA M, IYAMA K, et al: Differential expres-
sion of two basement membrane collagen genes, COL4A6 and
COL4A5, demonstrated by immunofluorescence staining using
1996 Kobayashi and Uchiyama: Recombinant type IV collagen in transfected cell strains
peptide-specific monoclonal antibodies. J Cell Biol 130:1219–1229,
1995
8. NAITO I, KAWAI S, NOMURA S, et al: Relationship between COL4A5
gene mutation and distribution of type IV collagen in male X-linked
Alport syndrome. Kidney Int 50:304–311, 1996
9. GUBLER MC, KNEBELMANN B, BEZIAU A, et al: Autosomal recessive
Alport syndrome: Immunohistochemical study of type IV collagen
chain distribution. Kidney Int 47:1142–1147, 1995
10. KNEBELMANN B, BREILLAT C, FORESTIER L, et al: Spectrum of muta-
tions in the COL4A5 collagen gene in X-linked Alport syndrome.
Am J Hum Genet 59:1221–1232, 1996
11. MINER JH, SANES JR: Collagen IV a3, a4, and a5 chains in rodent
basal laminae: Sequence, distribution, association with laminins, and
developmental switches. J Cell Biol 127:879–891, 1994
12. NIWA H, YAMAMURA K, MIYAZAKI J: Efficient selection for high-
expression transfectants with a novel eukaryotic vector. Gene
108:193–200, 1991
13. IMAI Y, MATSUSHIMA Y, SUGIMURA T, TERADA M: A simple and
rapid method for generating a deletion by PCR. Nucleic Acids Res
19:2785, 1991
14. BYERS PH: Disorders of collagen biosynthesis and structure, in
The Metabolic and Molecular Bases of Inherited Disease (vol. 4),
edited by SCRIVER CR, BEAUDET AL, SLY WS, VALLE D, New York,
McGraw-Hill, 2001, pp 5241–5285
15. CROUCH E, SAGE H, BORNSTEIN P: Structural basis for apparent het-
erogeneity of collagens in human basement membranes: Type IV
procollagen contains two distinct chains. Proc Natl Acad Sci USA
77:745–749, 1980
16. TRUEB B, GROBLI B, SPIESS M, et al: Basement membrane (type IV)
collagen is a heteropolymer. J Biol Chem 257:5239–5245, 1982
17. GUNWAR S, BALLESTER F, NOELKEN ME, et al: Glomerular basement
membrane: Identification of a novel disulfide-cross-linked network
of a3, a4, and a5 chains of type IV collagen and its implication for
the pathogenesis of Alport syndrome. J Biol Chem 273:8767–8775,
1998
18. BOUTAUD A, BORZA DB, BONDAR O, et al: Type IV collagen of the
glomerular basement membrane: Evidence that the chain speci-
ficity of network assembly is encoded by the noncollagenous NC1
domains. J Biol Chem 275:30716–30724, 2000
19. HEIKKILA P, TIBELL A, MORITA T, et al: Adenovirus-mediated trans-
fer of type IV collagen a5 chain cDNA into swine kidney in vivo:
Deposition of the protein into the glomerular basement membrane.
Gene Therapy 8:882–890, 2001
20. NISCHT R, POTTGIESSER J, KRIEG T, et al: Recombinant ex-
pression and properties of the human calcium-binding extra-
cellular matrix protein BM-40. Eur J Biochem 200:529–536,
1991
21. FOX JW, MAYER U, NISCHT R, et al: Recombinant nidogen consists of
three globular domains and mediates binding of laminin to collagen
type IV. EMBO J 10:3137–3146, 1991
22. CHEN M, COSTA FK, LINDVAY CR, et al: The recombinant expres-
sion of full-length type VII collagen and characterization of molecu-
lar mechanisms underlying dystrophic epidermolysis bullosa. J Biol
Chem 277:2118–2124, 2002
23. SAITO K, NAITO I, SEKI T, et al: Differential expression of mouse
a5(IV) and a6(IV) collagen genes in epithelial basement mem-
branes. J Biochem 128:427–434, 2000
24. MINER JH, SANES JR: Molecular and functional defects in kidneys
of mice lacking collagen a3(IV): Implications for Alport syndrome.
J Cell Biol 135:1403–1413, 1996
25. COSGROVE D, MEEHAN DT, GRUNKEMEYER JA, et al: Collagen
COL4A3 knockout: a mouse model for autosomal Alport syn-
drome. Genes Dev 10:2981–2992, 1996
26. LEINONEN A, NETZER KO, BOUTAUD A, et al: Goodpasture antigen:
Expression of the full-length a3(IV) chain of collagen IV and lo-
calization of epitopes exclusively to the noncollagenous domain.
Kidney Int 55:926–935, 1999
27. FUKUDA K, HORI H, UTANI A, et al: Formation of recombinant triple-
helical [a1(IV)]2a2(IV) collagen molecules in CHO cells. Biochem
Biophys Res Commun 231:178–182, 1997
28. NAGATA K: Hsp47: A collagen-specific molecular chaperone. Trends
Biochem Sci 21:23–26, 1996
29. LANGEVELD JPM, NOELKEN ME, HARD K, et al: Bovine glomeru-
lar basement membrane. Location and structure of the asparagine-
linked oligosaccharide units and their potential role in the
assembly of the 7S collagen IV tetramer. J Biol Chem 266:2622–
2631, 1991
30. NAYAK BR, SPIRO RG: Localization and structure of the asparagine-
linked oligosaccharides of type IV collagen from glomerular base-
ment membrane and lens capsule. J Biol Chem 266:13978–13987,
1991
31. HOSTIKKA SL, EDDY RL, BYERS MG, et al: Identification of a dis-
tinct type IV collagen a chain with restricted kidney distribu-
tion and assignment of its gene to the locus of X chromosome-
linked Alport syndrome. Proc Natl Acad Sci USA 87:1606–1610,
1990
